New prospects for urolithiasis metaphylaxis in Russia. Advisory board resolution (October 30, 2024)

Advisory board was held in Moscow on October 30, 2024, dedicated to the problem of preventing relapses (metaphylaxis) of urolithiasis. The next questions were discussed during the meeting: the cost-effectiveness of urolithiasis metaphylaxis in the Russian Federation, what kind of patients and in what cases it is indicated, what parameters should be used to select a remedy for urolithiasis metaphylaxis. A discussion was held on the prospects for introducing metaphylaxis into urological practice in connection with the release of updated clinical guidelines for urolithiasis by the Ministry of Health of the Russian Federation, in particular, a new section on anti-relapse therapy for the disease. This section includes components of the Lit-Control® Litura® line of products that have a scientific basis and high potential in urolithiasis metaphylaxis. This line of products can be recommended for long-term use by patients with urolithiasis, from 3 months or more, with the selection of a product depending on the chemical composition of the stone and metabolic disorders, including urine acidity.